Skip to main content

Advertisement

SpringerLink
Log in

Three percent diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses: a meta-analysis of the recent studies

  • Hot Clinical Study
  • Published:
Archives of Dermatological Research Aims and scope Submit manuscript

Abstract

Three percent diclofenac in 2.5% hyaluronan gel (DHA) is approved by the Food and Drug Administration (FDA) in the treatment of actinic keratoses (AK). We conducted a meta-analysis of the few prospective studies that evaluated the effect of DHA on the target lesion number score TLNS0 (indicating complete resolution of all target lesions in the treatment area) and/or the cumulative target lesion number score CLNS0 (indicating resolution of the target and new lesions in the treatment area) with assessment 30 days after the end of treatment. A comprehensive search of the 1966–2005 MEDLINE database and review of the reference lists of relevant articles identified the published randomised trials. Three studies were included, with a total of 364 patients. The placebo was the hyaluronan vehicule gel (HAV). The intention-to-treat analyses show that DHA significantly improve the TLNS0 (OR= 3.72; 95% CI=2.05–6.74) and the CLNS0 (OR=4.09; 95% CI=2.55–6.56) compare to HAV. Overall, 42/106 (39.6% CI: 30.8– 49.1%) had a TLNS0 with mean treatment duration of 75 days ± 21 [mean±standard deviation (SD)], and 70/179 (39.1% CI:32.3–46.4%) patients had a CLNS0 with a mean 78 days±16 treatment duration. DHA is effective compared to HAV in the treatment of AK. Further studies should establish subgroup analyses according to sites and severity of the AK lesions in order to determine if more patients could be improved in restricted indications. Biopsies, a longer follow-up evaluation, and comparisons with the other treatments of AK will also be helpful in the future to define the place of this treatment in the management of AK.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Adamson DJA, Frew D, Tatoud R et al (2002) Diclofebac antagonizes peroxisome proliferator-activated receptor-γ signalling. Mol Pharmacol 61:7–12

    Article  PubMed  CAS  Google Scholar 

  2. Alam CAS, Seed MP, Willoughby DA (1995) Angiostasis and vascular regression in chronic granulomatous inflammation induced by diclofenac in combination with hyaluronan in mice. J Pharm Pharmacol 47:407–411

    PubMed  CAS  Google Scholar 

  3. Arrich J, Piribauer F, Mad P et al (2005) Intra-articular hyaluronic acid for the treatment of osteoarthritis of the knee: systematic review and meta-analysis. CMAJ 172:1039–1043

    PubMed  Google Scholar 

  4. Brown MB, Mariott C, Martin GP (1995) A study of the transdermal drug delivery properties of hyaluronan. Round Table Series 40:53–71

    CAS  Google Scholar 

  5. Brown M, Jones S (2005) Hyaluronic acid: a unique topical vehicle for the localized delivery of drugs to the skin. J Eur Acad Dermatol Venereol 19:308–318

    Article  PubMed  CAS  Google Scholar 

  6. Buckman SY, Gresham A, Hale P et al (1998) COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis 19:723–729

    Article  PubMed  CAS  Google Scholar 

  7. Burkhart CN, Burkhart CG (2002) Reassessment of topical diclofenac/hyaluronan gel for actinic keratoses. Int J Dermatol 41:371–373

    Article  PubMed  Google Scholar 

  8. Cabrera PV, Blanco G, Alaniz L et al (2004) CD44 and hyaluronic acid regulate in vivo iNOS expression and metalloproteinase activity in murine air-pouch inflammation. Inflamm Res 53:556–566

    Article  PubMed  CAS  Google Scholar 

  9. Dentener MA, Vernooy JH, Hendriks S et al (2005) Enhanced levels of hyaluronan in lung of patients with COPD: relationship with lung function and local inflammation. Tohrax 60:114–119

    Article  CAS  Google Scholar 

  10. Dinehart SM (2000)The treatment of actinic keratoses. J Am Acad Dermatol 42:525–528

    Article  Google Scholar 

  11. Gebauer K, Brown P, Varigos G (2003) Topical diclofenac in hyaluronan gel for the treatment of solar keratoses. Austr J Dermatol 44:40–43

    Article  Google Scholar 

  12. Glogau RG (2000) The risk of progression to invasive disease. J Am Acad Dermatol 42:S23–S24

    Article  Google Scholar 

  13. Hascall VC, Majors AK, De la Motte CA et al (2004) Intracellular hyaluronan; a new frontier for inflammation? Biochim Biophys Acta 1673:3–12

    PubMed  CAS  Google Scholar 

  14. Jarvis B, Figgit DP (2003) Topical 3%diclofenac in a 2.5% hyaluronic acid gel. A review of its use in patients with actinic keratoses. Am J Clin Dermatol 4(3):203–213

    Article  PubMed  Google Scholar 

  15. Masferrer JL, Leahy KM, Koki AT et al (2000) Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60:1306–1311

    PubMed  CAS  Google Scholar 

  16. McEwan LE, Smith JG (1997) Topical diclofenac/hyaluronic acid gel in the treatment of solar keratoses. Austr J Dermatol 38:187–189

    Article  CAS  Google Scholar 

  17. Moore AR, Willoughby DA (1995) Hyaluronan as a drug delivery system for diclofenac: a hypothesis for mode of action. Int J Tissue React 17:153–156

    PubMed  CAS  Google Scholar 

  18. Mortier L, Marchetti P, Delaporte E et al (2002) Progression of actinic keratosis to squamous cell carcinoma of the skin correlates with deletion of the 9p21 region encoding the p16INK4a tumor suppressor. Cancer Lett 176:205–214

    Article  PubMed  CAS  Google Scholar 

  19. Nawrat P, Surazynki A, Karna E et al (2005) The effect of hyaluronic acid on interleukin-1-induced deregulation of collagen metabolism in cultured human skin fibroblasts. Pharmacol Res 51:473–477

    PubMed  CAS  Google Scholar 

  20. Nelson C, Rigel D, Smith S, Swanson N, Wolf J (2004) Phase IV, open-label assessment of the treatmentof actinic keratosis with 3%diclofenac sodium topical gel (SolarazeTM). J Drugs Dermatol 3(4):401–407

    PubMed  Google Scholar 

  21. Novaes AC, Schaiquevich P, Nasswetter G (2005) Multicenter study of hyaluronic acid obtained by biotechnology to evaluate clinical efficacy and safety in knee osteoarthritis. Int J Clin Pharmacol res 25:1–7

    PubMed  CAS  Google Scholar 

  22. Pistorius A, martin M, Willershausen B et al (2005) The clinical application of hyaluronic acid in gingivitis therapy. Quintescence Int 36:531–538

    Google Scholar 

  23. Rivers JK, McLean DI (1997) An open study to assess the efficacy and safety of topical 3%diclofenac in a 2.5%hyaluronan acid gel for the treatment of actinic keratoses. Arch Dermatol 133:1239–1242

    Article  PubMed  CAS  Google Scholar 

  24. Rivers JK, Arlette J, Shear N, Guenther L, Carey W, Poulin Y (2002) Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. Br J Dermatol 146:94–100

    Article  PubMed  CAS  Google Scholar 

  25. Silapunt S, Goldberg LH, Alam M (2003) Topical and light-based treatments for actinic keratoses. Sem Cut Med Surg 22(3):162–170

    Article  Google Scholar 

  26. Spencer JM, Kahn SM, Jiang W et al (1995) Activated ras genes occur in human actinic keratoses, premalignant precursors to squamous cell carcinoma. Arch Dermatol 131:796–800

    Article  PubMed  CAS  Google Scholar 

  27. Weindl G, Schaller M, Schafer-Korting M et al (2004) Hyaluronic acid in the treatment and prevention of skin diseases: molecular biological, pharmaceutical and clinical aspects. Skin Pharmacol Physiol 17:207–213

    Article  PubMed  CAS  Google Scholar 

  28. Wolf JE, Taylor JR, Tschen E, Kang S (2001) Topical 3.0% diclofenac gel in the treatment of actinic keratoses. Int J Dermatol 40:709–713

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, Erasme Hospital, Erasme universitary Hospital, Route de Lennik, 808, 1070, Brussels, Belgium

    D. Pirard, P. Vereecken & M. Heenen

  2. Intensive Care, Erasme Hospital, Erasme universitary Hospital, Route de Lennik, 808, 1070, Brussels, Belgium

    C. Mélot

  3. Chaussée de Charleroi, 212, 1060, Brussels, Belgium

    D. Pirard

Authors
  1. D. Pirard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Vereecken
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Mélot
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Heenen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D. Pirard.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pirard, D., Vereecken, P., Mélot, C. et al. Three percent diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses: a meta-analysis of the recent studies. Arch Dermatol Res 297, 185–189 (2005). https://doi.org/10.1007/s00403-005-0601-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00403-005-0601-9

Keywords

Search

Navigation